Doc2b enrichment enhances glucose homeostasis in mice via potentiation of insulin secretion and peripheral insulin sensitivity. by Ramalingam, Latha et al.
Doc2b enrichment enhances glucose homeostasis in mice via 
potentiation of insulin secretion and peripheral insulin 
sensitivity
Latha Ramalingam1, Eunjin Oh2, and Debbie C. Thurmond1,2,3
1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 
Indianapolis, IN, USA
2Department of Pediatrics, Herman B Wells Center for Pediatric Research, Basic Diabetes Group, 
Indiana University School of Medicine, Indianapolis, IN 46202, USA
3Department of Cellular and Integrative Physiology, Indiana University School of Medicine, 
Indianapolis, IN, USA
Abstract
Aims/hypothesis—Insulin secretion from pancreatic beta cells and insulin-stimulated glucose 
uptake into skeletal muscle are processes regulated by similar isoforms of the soluble N-
ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) and mammalian homologue 
of unc-18 (Munc18) protein families. Double C2 domain β (Doc2b), a SNARE- and Munc18-
interacting protein, is implicated as a crucial effector of glycaemic control. However, whether 
Doc2b is naturally limiting for these processes, and whether Doc2b enrichment might exert a 
beneficial effect upon glycaemia in vivo, remains undetermined.
Methods—Tetracycline-repressible transgenic (Tg) mice engineered to overexpress Doc2b 
simultaneously in the pancreas, skeletal muscle and adipose tissues were compared with wild-type 
(Wt) littermate mice regarding glucose and insulin tolerance, islet function in vivo and ex vivo, 
and skeletal muscle GLUT4 accumulation in transverse tubule/sarcolemmal surface membranes. 
SNARE complex formation was further assessed using Doc2b overexpressing L6 GLUT4-myc 
myoblasts to derive mechanisms relatable to physiological in vivo analyses.
Results—Doc2b Tg mice cleared glucose substantially faster than Wt mice, correlated with 
enhancements in both phases of insulin secretion and peripheral insulin sensitivity. Heightened 
peripheral insulin sensitivity correlated with elevated insulin-stimulated GLUT4 vesicle 
accumulation in cell surface membranes of Doc2b Tg mouse skeletal muscle. Mechanistic studies 
demonstrated Doc2b enrichment to enhance syntaxin-4–SNARE complex formation in skeletal 
muscle cells.
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Conclusions/interpretation—Doc2b is a limiting factor in SNARE exocytosis events 
pertinent to glycaemic regulation in vivo. Doc2b enrichment may provide a novel means to 
simultaneously boost islet and skeletal muscle function in vivo in the treatment and/or prevention 
of diabetes.
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Introduction
Insulin secretion and insulin action are critical for normal glucose homeostasis. Defects in 
both of these processes lead to type 2 diabetes. Glucose-stimulated insulin secretion (GSIS) 
from islet beta cells and insulin-stimulated glucose uptake into peripheral tissues are 
mediated by similar exocytotic mechanisms involving a family of soluble N-
ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) protein isoforms. 
SNARE-mediated exocytosis requires the association of two target membrane (t)-SNARE 
proteins (syntaxins and synaptosome-associated proteins [SNAPs]) with one vesicle/granule 
membrane (v)-SNARE protein (VAMP) to form a heterotrimeric SNARE core complex, 
which promotes docking and fusion of vesicles/granules. SNARE protein-mediated GSIS 
from islet beta cells is biphasic. The two glucose-stimulated phases are proposed to be 
supported by differing pools of VAMP2-localised granules mobilised to differing SNARE 
protein isoform binding sites at the cell surface, including syntaxin 1A (Syn1A), syntaxin 3 
(Syn3), syntaxin 4 (Syn4) and SNAP25 (or SNAP23) [1–5]. The v-SNARE protein VAMP8 
also functions in insulin secretion but is required selectively for glucagon-like peptide 
(GLP)-1-enhanced GSIS [6]. Similarly, insulin-stimulated glucose uptake into skeletal 
muscle and adipose cells involves the recruitment of VAMP2-bound vesicles containing the 
insulin-responsive GLUT4 to the cell surface (as reviewed in [7]), yet involves a smaller 
subset of SNARE isoforms at the cell surface: Syn4 and SNAP23 [8–10]. Hence, towards 
achieving normoglycaemia, targeting these Syn4-based mechanisms is desirable because 
they are limiting for both GSIS and insulin-stimulated glucose uptake [8, 11].
Syntaxin proteins are regulated by specific high-affinity binding partners (mammalian 
homologue of unc-18 [Munc18] proteins). Three Munc18 isoforms are involved in one or 
both phases of glucose-stimulated insulin release, Munc18-1, Munc18b and Munc18c [12–
14]. Only one isoform, Munc18c, is involved in insulin-stimulated GLUT4 vesicle 
translocation [15–17]. Munc18c is the only isoform capable of pairing with Syn4 in these 
cell types [18] and this pairing is altered when Munc18c becomes tyrosine phosphorylated in 
response to physiologically relevant stimuli [19–22]. However, details regarding the purpose 
of Munc18c in these complexes remain controversial.
Our earlier studies have suggested that decreased Munc18c–Syn4 binding occurs 
concomitantly with increased binding of double C2 domain protein β (Doc2b) to Munc18c, 
and that Doc2b preferentially binds tyrosine-phosphorylated Munc18c [23, 24]. Doc2b is a 
ubiquitously expressed soluble protein that can localise to the plasma membranes (PM) of 
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beta cells, adipocytes and skeletal muscles [24–27]. Doc2b has also been shown to bind to 
Syn4 in clonal beta cells and 3T3L1 adipocytes [26, 27] and has been suggested to alter 
membrane bending via binding to Syn4-based SNARE complexes in vitro [28]. Despite the 
discrepant mechanistic data, there is cohesive unified support for the role of Doc2b as a 
potentially limiting factor in GSIS and glucose uptake. Moreover, a possible association 
between Doc2b deficiency and diabetes in rodents exists [29]. Taken together these data 
raise the possibility that intentional elevation of Doc2b in vivo could provide a means to 
simultaneously rescue aberrations in insulin secretion and insulin action.
As a first step towards testing this possibility, we generated regulatable Doc2b transgenic 
(Tg) mice using a targeting vector known to drive expression selectively in the pancreas, 
skeletal muscle and adipose tissue [11, 30, 31]. Indeed, elevated levels of Doc2b in these 
tissues in vivo resulted in improved glucose and insulin tolerance relative to wild-type (Wt) 
littermate mice. Mechanistically, these improvements were underscored by enhanced Syn4-
based SNARE complex formation and exocytosis function in Doc2b Tg islets and skeletal 
muscle, altogether consistent with the concept that Doc2b is limiting for these processes in 
vivo. These data suggest that Doc2b enrichment may provide the means to confer superior 
whole-body glucose homeostasis.
Methods
Materials
Rabbit anti-Munc18c and rabbit anti-Syn4 antibodies were generated in-house as described 
[17, 32]. The rabbit anti-Syn4 antibody used for immunoprecipitation was purchased from 
Chemicon (Temecula, CA, USA). SNAP23 and SNAP25 antibodies were purchased from 
Affinity Bioreagents (Golden, CO, USA). The Doc2b antibody was purchased from Abcam 
(Cambridge, MA, USA). The Munc18-1 and VAMP2 antibodies were acquired from 
Synaptic Systems (Gottingen, Germany). The Syn1A antibody was obtained from Sigma (St 
Louis, MO, USA). The Akt and phosphoserine (Ser 473)-specific Akt antibodies were 
purchased from Cell Signaling (Beverley, MA, USA). Goat anti-rabbit–horseradish 
peroxidase and anti-mouse– horseradish peroxidase secondary antibodies were purchased 
from Bio-Rad (Hercules, CA, USA). Protein G+ agarose beads and anti-GLUT4 antibody 
were acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The rat insulin 
radioimmunoassay kit was acquired from Millipore (Billerica, MA, USA). The enhanced 
chemiluminescence (ECL) kit was purchased from Amersham Biosciences (Pittsburgh, PA, 
USA). Humulin R was obtained from Eli Lilly (Indianapolis, IN, USA).
Animals and in vivo procedures
All studies involving mice followed the Guidelines for the Use and Care of Laboratory 
Animals. The pUC-CombiCMV vector [30] (a kind gift from U. Certa, Roche, Basel, 
Switzerland) was used to generate tetracycline (tet)-repressible Doc2b-overexpressing Tg 
mice. The vector contains a tetO minimal promoter to drive the target gene (Doc2b in this 
case) in one direction, and a CMV promoter to drive the tet-transactivator gene in the other 
direction (see ESM Methods for details). This vector has been shown to drive expression 
primarily in the pancreas, fat and skeletal muscle and not in the brain, heart, liver, spleen, 
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kidney or lung [11, 30, 31]. Mice were generated and maintained on the C57BL/6J genetic 
background; breeders to expand the initial colony were purchased from Jackson Laboratory 
(Bar Harbor, ME, USA). Female Doc2b Tg and Wt mice (4–6 months old) were fasted for 6 
h (08:00–14:00 hours) before intraperitoneal glucose tolerance test (IPGTT) and insulin 
tolerance test (ITT) analyses as previously described [24] (see ESM Methods). Mouse 
pancreatic islets were isolated and perifusion performed as previously described [24, 33] 
(see ESM Methods). Skeletal muscle subcellular fractionation and immunoprecipitation 
assays were performed as previously described [24, 34] (see ESM Methods).
Cell culture, transient transfection and binding assays
Rat L6 muscle cells stably expressing GLUT4 with an exofacial myc-epitope (a gift from A. 
Klip, Department of Biochemistry, University of Toronto, Toronto, Canada) were cultured 
as previously described [35] (see ESM Methods). Myoblasts were electroporated (0.20 kV 
and 960 μFarad) with 150 μg of green fluorescent protein (GFP) vector or GFP–Doc2b 
plasmid DNA per 10 cm2 dish. After electroporation, cells were allowed to adhere to plates 
for 48 h. Cells were pre-incubated in serum-free media for 2 h followed by stimulation for 5 
min with 100 nmol/l insulin. Cells were harvested in 1% NP-40 lysis buffer and detergent 
lysates were used for co-immunoprecipitation or glutathione S transferase (GST)–VAMP2 
interaction assays, as described previously [32] (see ESM Methods).
Statistical analysis
All data were evaluated for statistical significance using Student's t test for comparison of 
two groups; ANOVA was used otherwise. Data are expressed as the average ± SE.
Results
Generation of Doc2b Tg mice
We generated tet-repressible Doc2b Tg mice using a targeting vector previously shown to 
drive expression almost exclusively in the pancreas, skeletal muscle and adipose tissue [11, 
31]. Of the four founder lines, three transmitted the Doc2b gene and one line consistently 
exhibited an approximately two- to threefold increase in Doc2b protein relative to 
endogenous expression in Wt littermates in these tissues (Fig. 1a). No alterations in the 
levels of SNARE proteins, such as Syn4, SNAP23, VAMP2 and Munc18c, were detected. 
The Doc2b protein level in Tg islets was increased by approximately threefold over that in 
Wt islets, again with no alteration in the expression of SNARE or Munc18 proteins (Fig. 
1b). No transgene expression was detected in heart, liver or spleen (Fig. 1c), or in whole-
brain lysate, cerebellum or hypothalamus (Fig. 1d), similar to the findings of other reports 
using this targeting vector [11, 31]. GLUT4 protein levels in the heart, skeletal muscle and 
fat of Doc2b Tg mice were similar to those in Wt mice (Fig. 1e).
Improved glucose tolerance in Doc2b-enriched mice
To determine whether Doc2b expression in these select tissues was limiting for glucose 
homeostasis in vivo, IPGTTs were performed. While fasting glycaemia was unaltered, 
Doc2b Tg mice showed significantly lower blood glucose levels than Wt mice upon glucose 
challenge at all time points (Fig. 2a). AUC analysis revealed this to be a 44% improvement 
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in glucose tolerance (Fig. 2b). This improved glucose clearance correlated with a 
significantly increased serum insulin content in the Doc2b Tg mice within the first 10 min 
after glucose injection during the IPGTT (Fig. 2c). Body weights and food intake of Doc2b 
Tg mice were equivalent to those of Wt mice over a 7- to 9-week period (ESM Fig. 1). The 
lower-expressing transgenic line (< 1.3-fold) was similar to Wt responsiveness in the IPGTT 
(ESM Fig. 2). These data suggested that an approximately two- to threefold enrichment of 
Doc2b simultaneously in skeletal muscle, fat and pancreas was sufficient to enhance glucose 
tolerance, perhaps via heightened insulin release and/or peripheral glucose uptake.
To validate that the enhanced glucose tolerance of the Doc2b Tg mice was due to the 
presence of the transgene, the same Doc2b Tg and Wt mice examined by IPGTT in Fig. 2a 
were administered tet-treated drinking water for 1 week to repress the transgene, after which 
the IPGTT was repeated. The glucose tolerance of the tet-treated Doc2b Tg mice was similar 
to that of the Wt mice (Fig. 3a, b), as were the Doc2b protein levels (Fig. 3c). These data 
confirmed that the enhanced glucose-tolerant phenotype of the Doc2b Tg mice corresponded 
to the expression of the Doc2b transgene.
Doc2b enrichment potentiates biphasic GSIS
To determine whether the increased serum insulin content of Doc2b Tg mice was related to 
increased islet function, we subjected islets to parallel perifusion analyses. Indeed, islets of 
Doc2b Tg mice exhibited a higher peak of first-phase insulin release as well as sustained 
elevation of second-phase release (Fig. 4a). AUC analysis of Doc2b Tg secretion revealed a 
50% increase over that of Wt islets in the first phase, and a 250% increase in second phase 
relative to Wt islets (Fig. 4b). Total insulin content was similar between Doc2b Tg and Wt 
islets (Fig. 4c). Basal insulin secretion was similar between Doc2b Tg and Wt islets (Fig. 
4a), consistent with similar fasting serum insulin contents of the mice (Fig. 2c). These data 
suggest that Doc2b is limiting for each phase of GSIS and that its enrichment could enhance 
functional GSIS without aberrantly raising basal insulin release.
Doc2b Tg mice have enhanced insulin sensitivity and cell surface GLUT4 accumulation in 
skeletal muscle
We next assessed whether the beneficial effect of Doc2b enrichment on glucose tolerance 
was related to improved peripheral insulin sensitivity by performing an ITT. Following 
insulin injection (0.75 U/kg body weight), blood glucose levels of the littermate Wt mice 
dropped by ∼45% within 60 min, as is normal for the C57BL/6J strain (Fig. 5a). In Doc2b 
Tg mice, both the rate and extent of the reduction in glycaemia was significantly enhanced 
(Fig. 5a); the area over the ITT curve for the Doc2b Tg mice showed this to be an almost 
twofold improvement in glycaemia compared with Wt mice (Fig. 5b).
The improved insulin sensitivity suggested that Doc2b may be limiting for insulin signalling 
or insulin-stimulated GLUT4 vesicle translocation to the cell surface membranes in skeletal 
muscle, given that skeletal muscle accounts for ∼80% of glucose uptake in humans [36]. To 
test this, transverse tubule/sarcolemmal cell-surface-enriched membrane fractions (referred 
to as PM) were isolated from saline- or insulin-injected hindlimb skeletal muscle of Doc2b 
Tg and Wt mice. PM fractions prepared from insulin-injected Wt mice showed the expected 
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∼1.5-fold increase in GLUT4 accumulation in insulin-stimulated vs unstimulated Wt mouse 
muscles [34]. Remarkably, Doc2b Tg PM fractions exhibited a ∼2.2-fold increase in 
insulin-stimulated GLUT4 vesicle accumulation at the PM (Fig. 6a). Since Akt activation in 
Doc2b Tg skeletal muscle homogenates was similar to that in the homogenates from Wt 
mice (Fig. 6b), the beneficial action of Doc2b enrichment appeared to lie downstream of Akt 
activation. Toward this, SNARE and Munc18 abundances were assessed for differences. 
While Doc2b levels were elevated in the Tg PM muscle fractions compared with Wt, as 
expected, Syn4 and Munc18c protein levels were similar between Doc2b Tg and Wt muscle 
PM fractions, under both unstimulated and insulin-stimulated conditions (Fig. 6c). 
Collectively, these data implicate enhanced insulin-stimulated GLUT4 vesicle accumulation 
(docking/fusion) at the PM as an underlying cause for the enhanced peripheral insulin 
sensitivity of the Doc2b Tg mice.
Doc2b enrichment promotes SNARE complex formation in skeletal myoblasts
To determine how Doc2b enrichment in skeletal muscle of the Doc2b Tg mice might 
increase the PM localisation of GLUT4, Munc18c–Syn4 binding and Syn4 activation/
SNARE complex formation was studied in L6-GLUT4-myc myoblasts transfected to 
express exogenous GFP-tagged Doc2b (or GFP vector control). L6-GLUT4-myc skeletal 
myoblasts are the premiere clonal muscle cell line for recapitulating the events associated 
with GLUT4 vesicle exocytosis and transfect with ∼30–50% efficiency. 
Immunoprecipitation of Syn4 from insulin-stimulated GFP–Doc2b-expressing L6 cells 
showed significantly reduced Munc18c co-precipitation compared with GFP-expressing 
cells (Fig. 7a). Syn4 accessibility to VAMP2 was examined as an indicator of its ability to 
form SNARE complexes, given the inability to obtain sufficient PM protein from transfected 
L6 cells for co-immunoprecipitation analyses. Syn4 accessibility to an exogenous GST–
VAMP2 protein linked to sepharose beads from insulin-stimulated GFP–Doc2b-expressing 
L6 myoblasts was significantly enhanced relative to cells expressing a similar amount of 
GFP (Fig. 7b). Endogenous Doc2b levels were similar among transfected cells, suggesting 
that the enrichment in SNARE complex formation was due to the effects of overexpressed 
Doc2b (ESM Fig. 3). The Doc2b antibody used for this and all Doc2b immunoblotting was 
confirmed to react specifically with Doc2b (ESM Fig. 4). Together, these results suggest 
that Doc2b is a limiting factor for Munc18c–Syn4 dissociation in skeletal muscle cells, and 
that the potentiation of Syn4 accessibility by increased expression of Doc2b may underlie 
the enhanced GLUT4 accumulation in PM fractions and the insulin sensitivity of the Doc2b 
Tg mice.
Discussion
In this study, we tested the concept that Doc2b is limiting for glucose homeostasis, and that 
enriching Doc2b might provide a means to simultaneously improve insulin sensitivity and 
insulin secretion in an effort to enhance whole-body glucose homeostasis in vivo. Using 
novel tet-repressible Doc2b Tg mice, we show that increasing the expression of Doc2b by 
approximately two- to threefold simultaneously in the pancreas, skeletal muscle and adipose 
tissue conferred enhanced glucose and insulin tolerance in vivo. The enhanced glucose 
tolerance in the Doc2b Tg mice was found to be mediated by the potentiation of both insulin 
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secretion and peripheral insulin action. Increased serum insulin content in Doc2b Tg mice 
post glucose injection is likely to be directly related to the improved GSIS in the islet beta 
cells. In our ex vivo islet studies, the second phase was particularly robust, consistent with 
clonal cell studies of Doc2b overexpression [25, 27]. It has been suggested that second-
phase release of insulin contributes substantially to the responsiveness of peripheral tissues, 
such as skeletal muscle. Interestingly, Doc2b enrichment also potentiated the first phase of 
insulin release and, because the first phase rapidly impacts hepatic glucose output [37], it 
remains possible that the liver glucose output rate was reduced rapidly to contribute to the 
overall improvement of glucose tolerance. Notably, the Doc2b Tg mice also showed 
significant enhancement in skeletal muscle insulin sensitivity and increased GLUT4 
accumulation at the cell surface. As such, the skeletal muscle would likely require less 
insulin to accomplish its task, and the need for sustained insulin release during the second 
phase may be reduced. Collectively, this Doc2b Tg mouse model provides the first proof-of-
principle evidence for the potential merit of Doc2b enrichment in glycaemic control. Future 
studies using skeletal muscle- and islet beta cell-specific Doc2b overexpressing mouse 
models will facilitate delineation of the relative contribution of Doc2b enrichment in these 
tissues to maintenance of glucose homeostasis. Further, comparison of such mice against 
mice overexpressing a dominant-negative Doc2b mutant, such as that referred to as ‘CIM’ 
[26], would be a useful control for the evaluating the merit of upregulating Doc2b in these 
tissues.
The positive effect of Doc2b enrichment upon peripheral insulin sensitivity and GLUT4 
accumulation at the cell surface of skeletal muscle suggests that endogenous Doc2b in 
skeletal muscle and/or fat is limiting for insulin-stimulated glucose clearance mechanisms. 
These in vivo and ex vivo skeletal muscle data validate an earlier report wherein Doc2b 
overexpression in 3T3-L1 adipocytes enhanced glucose uptake [26]. Our data support an 
indirect role for Doc2b in its potentiation of skeletal muscle insulin action at the level of 
SNARE complex formation for the following reasons: (1) Doc2b in skeletal muscle lysates 
failed to co-precipitate with Syn4 [24] and (2) the overexpression of Doc2b in L6 myoblasts 
failed to drive an interaction of Doc2b with Syn4. These findings in primary skeletal muscle 
tissue do not recapitulate the binding interactions derived from in vitro mixing assays using 
recombinant Doc2b [28]. This discrepancy may suggest that these Doc2b/Munc18c/Syn4 
interactions are affected by additional factors such as the particular cellular milieu, post-
translational modification of the proteins involved and/or by calcium. For example, insulin 
triggers the tyrosine phosphorylation of Munc18c in skeletal muscle and adipocytes [20–24, 
38], enhancing the affinity of Munc18c for Doc2b by almost twofold while decreasing its 
affinity for Syn4. These data are congruent with a model whereby Doc2b would seemingly 
titrate out more Munc18c to make more cellular Syn4 accessible, generating more Syn4-
based docking/fusion sites for incoming GLUT4 vesicles. Another possible manner by 
which Doc2b enrichment potentiates GLUT4 exocytosis is via its recently described role in 
calcium-induced membrane curvature induction [28]. However, earlier findings suggest that 
the actions of calcium-activated Doc2b in bona fide skeletal muscle may differ from those 
seen in vitro, or in neurons and adipocytes [26, 39], and as such remains to be tested. Like 
GLUT4 vesicle exocytosis, insulin granule exocytosis uses Syn4-based SNARE complexes; 
Syn4 has an impact on both phases of GSIS [3]. Since second-phase insulin exocytosis 
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requires Munc18c and hinges upon Munc18c's ability to undergo glucose-induced tyrosine 
phosphorylation, the requirement and the role of Doc2b may be linked indirectly to Syn4 in 
mechanism(s) similar to that described above for skeletal muscle [19, 21]. Another 
possibility involves the concept that SNARE complexes regulated by Doc2b could affect 
different granule pools that may drive biphasic insulin secretion, as seen with Munc18b [12]. 
Consistent with this, Doc2b can also bind to Munc18-1, albeit through a different C2 
domain [40], and Munc18-1 functions in first-phase secretion [13, 41]. Future studies using 
total internal reflection fluorescence microscopy will be required to distinguish the effects of 
Doc2b enrichment upon the different pools of insulin granules.
In summary, the data presented show that Doc2b has promise as a new therapeutic target for 
the management of pre-clinical and frank type 2 diabetes and demonstrate that its use is 
feasible and safe for betterment of glycaemic control in vivo; the data also provide insight 
into the mechanisms of Doc2b action, particularly in SNARE-mediated exocytotic events, 
which may prove valuable in future drug design strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
Doc2b Double C2 domain β
GFP Green fluorescent protein
GLP Glucagon-like peptide
GST Glutathione S transferase
GSIS Glucose-stimulated insulin secretion
IPGTT Intraperitoneal glucose tolerance test
ITT Insulin tolerance test
Munc18 Mammalian homologue of unc-18
PM Plasma membrane
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SNAP Synaptosome-associated protein
SNARE Soluble N-ethylmaleimide-sensitive factor-attachment protein receptor
Syn1A Syntaxin 1A
Syn4 Syntaxin 4
tet Tetracycline
Tg Transgenic
t-SNARE Target SNARE
VAMP Vesicle-associated membrane protein
v-SNARE Vesicle SNARE
Wt Wild type
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Fig. 1. 
Protein expression in tissues of Doc2b transgenic mice. (a) Gastrocnemius skeletal muscle 
(Musc), pancreas (Panc) and epigonadal fat were isolated from three to five pairs of Doc2b 
Tg mice (black bars) and Wt littermates (white bars) and immunoblotted (IB) for detection 
of SNARE and SNARE accessory proteins. Doc2b abundances were normalised to clathrin 
to account for minor variations in protein loading; *p<0.05 vs Wt. (b) Isolated islets were 
assessed for Doc2b and SNARE protein expression as described in (a) above. (c, d) Heart, 
liver and spleen were similarly assessed for Doc2b levels (c), as was whole-brain lysate, 
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cerebellum (Cere) and hypothalamus (Hypo) (d). (e) GLUT4 protein abundance was 
assessed in heart, skeletal muscle and fat from mice from panel (a). Data are representative 
of three to five pairs of mice. AU, arbitrary units
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Fig. 2. 
Doc2b Tg mice have enhanced glucose tolerance. (a) IPGTT in Doc2b Tg mice (black 
squares) and Wt littermates (white diamonds) was performed in 4- to 6-month-old female 
mice fasted for 6 h. (b) AUC data are shown as the average ± SE from seven pairs of mice; 
*p<0.05, vs Wt. (c) Insulin content present in serum taken before (Basal) and 10 min post 
injection of glucose (Stimulated) during the IPGTT in Doc2b Tg (black bars) and Wt mice 
(white bars). Data represent the average ± SE from six pairs of mice; *p<0.05 vs Wt 
basal; †p<0.05 vs Wt glucose-stimulated
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Fig. 3. 
Tet-mediated repression of the Doc2b transgene reduces glucose tolerance compared with 
that of the Wt mice. (a) Doc2b Tg (black squares) and Wt (white diamonds) female mice 
assessed in Fig. 2 assays were subsequently administered tet (1 mg/ml) in the drinking water 
for 1 week and the IPGTT was re-performed. (b) AUC analysis is shown as the average ± 
SE from seven pairs of mice. (c) Tissue extracts were immunoblotted and quantified as 
described in Fig. 1 for Doc2b Tg (black bars) and Wt mice (white bars). Data represent the 
average ± SE of three independent sets of tissues
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Fig. 4. 
Islets from Doc2b Tg mice exhibit potentiated biphasic insulin release. (a) Islets isolated 
from Doc2b Tg mice (black squares) and Wt littermates (white diamonds) were perifused in 
parallel at 2.8 mmol/l glucose for 10 min followed by 16.7 mmol/l glucose for 35 min and 
then returned to low glucose for 20 min. Eluted fractions were collected and insulin 
secretion was determined by RIA, as depicted in this representative pair of traces. (b) AUC 
for first (11–17 min) and second (18–45 min) phases of insulin secretion was quantified in 
islets, normalised to baseline, from Doc2b Tg (black bars) and Wt (white bars) mice. Data 
represent the average ± SE from three independent sets of perifused islets; *p<0.05 vs Wt 
(Wt set equal to 1.0 and Tg normalised thereto for each phase per set). (c) Average insulin 
content per 10 islets from Doc2b Tg mice and Wt littermates
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Fig. 5. 
Doc2b Tg mice exhibit enhanced insulin sensitivity. (a) Insulin tolerance testing of seven 
pairs of female Doc2b Tg mice (black squares) and Wt littermates (white diamonds) fasted 
for 6 h. Data are shown as the mean percentage of starting basal blood glucose 
concentrations ± SE; *p<0.05 vs Wt. (b) Area over the curve (AOC) data are shown as the 
average ± SE from seven pairs of mice; *p<0.05, vs Wt
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Fig. 6. 
Doc2b Tg mice show increased insulin-stimulated GLUT4 accumulation at the sarcolemma/
transverse tubule PMs of skeletal muscle. (a) GLUT4 abundance in the PM fractions was 
detected by immunoblot (Ponceau S shows protein loading). Quantification of GLUT4 
accumulation in PM fractions is shown in the adjacent bar graph where data are shown as 
the average ± SE for three sets of mice; *p<0.05 vs Wt basal, †p<0.05 vs Tg basal. (b) 
Whole skeletal muscle detergent homogenates from mice stimulated with insulin were 
immunoblotted for activated Akt (p-AktS473). Blots were stripped and reprobed for total Akt 
content. Data are representative of three independent sets of tissue homogenates. (c) PM 
fractions prepared from Doc2b Tg mice (black bars) and Wt littermates (white bars) from 
panel (a) were immunoblotted for Doc2b, Munc18c and Syn4. Data are shown as the 
average ± SE for three sets of mice. While Doc2b was significantly elevated in Tg vs Wt 
fractions (*p<0.05), no statistical differences in either Syn4 or Munc18c abundances were 
observed. AU, arbitrary units
Ramalingam et al. Page 18
Diabetologia. Author manuscript; available in PMC 2015 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 7. 
Overexpression of Doc2b coordinately decreases Munc18c–Syn4 binding while increasing 
Syn4 activation in L6 GLUT4-myc myoblasts. Detergent lysates prepared from L6 GLUT4-
myc myoblasts transfected to express GFP-tagged Doc2b or GFP alone and stimulated with 
insulin for 5 min were used in anti-Syn4 immunoprecipitation reactions and co-precipitated 
Munc18c or Doc2b proteins were detected by immunoblotting (a), or in GST-VAMP2 
interaction assays for detection of the Syn4 present in lysates that is accessible to the 
exogenous GST–VAMP2 probe (b). Proteins were immunoblotted for Syn4, GST and GFP 
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or GFP–Doc2b (∼75 kDa). Quantification is represented in the adjacent bar graphs. Data are 
representative of the average ± SE of three independent experiments of the ratio of 
Munc18c/Syn4 (%), and Syn4/GST–VAMP2 (fold), respectively; *p<0.05 vs GFP
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